Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2022 | Modulating the gut microbiome to improve immune checkpoint inhibitor efficacy

Nazli Dizman • 6 Jun 2022
ASCO 2022
General

Nazli Dizman, MD, Yale University School of Medicine, New Haven, CT, talks on the association of the gut microbiome with response to immunotherapies and modulating the gut microbiome to improve outcomes with immune checkpoint inhibitors. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.

More from Nazli Dizman

1:27
Unmet needs regarding immunotherapy for renal cell carcinoma
Nazli Dizman • 24 Feb 2023
5:07
Association between time-of-day of ICI infusion and disease outcomes in metastatic RCC)
Nazli Dizman • 24 Feb 2023
3:27
Characterization of the microbial resistome in a prospective trial of CBM588 in mRCC
Nazli Dizman • 6 Jun 2022
0:50
The mechanism of action of CBM588, a live bacteria product for increasing IO efficacy
Nazli Dizman • 6 Jun 2022

Related Videos

0:29
Innovative ctDNA-based liquid biopsy techniques for cancer diagnosis
Alain Thierry • 9 Apr 2024
0:50
Employing fragmentomics as a novel strategy to characterize and detect cancers
Alain Thierry • 9 Apr 2024
1:27
Emerging trials in melanoma: SWOG S1801, OpACIN-neo and PRADO
Christoffer Gebhardt • 9 Apr 2024
3:10
PALOMA: subcutaneous amivantamab in advanced solid tumors
Natasha Leighl • 17 Apr 2024
The content of VJOncology is intended for healthcare professionals